MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influe...
| Model | Near-Term (0-3 mo.) | Mid-Term (3-12 mo.) | Long-Term (1-5 yr.) |
|---|---|---|---|
| Deepseek | Hold | Buy | Buy |
| OpenAI | Buy | Hold | Hold |
| Gemini | Buy | Hold | Hold |
| Grok | Buy | Hold | Sell |
High volatility and negative PE suggest caution in the short term.
Potential for recovery as market conditions stabilize and company progresses.
Strong sector position and innovation potential support long-term growth.
Price above 50-day average suggests upward momentum, but negative P/E raises concerns.
High beta indicates volatility; hold until clearer earnings and pipeline progress.
Long-term potential depends on successful pipeline and market diversification beyond COVID.
Recent price surge suggests a short-term upward momentum.
Uncertainty in sustained growth or profitability in the medium term.
Long-term potential but dependent on significant strategic shifts.
Current price above 50-day average suggests upward momentum. Potential for short-term gains.
Price below 200-day average signals potential weakness. High beta suggests volatility.
Negative valuation and high beta indicate sustained risk. Long-term profitability uncertain.
